GLUD2: A Potential Drug Target and Biomarker for Glutamate Dehydrogenase 2-Inhibition

Target Name: GLUD2

NCBI ID: G2747

GLUD2

GLUD2: A Potential Drug Target and Biomarker for Glutamate Dehydrogenase 2-Inhibition

Glutamate dehydrogenase 2 (GLUD2) is a protein that is expressed in various tissues and cell types in the human body. It is a key enzyme in the metabolism of glutamate, a neurotransmitter that plays a crucial role in neural communication. GLUD2 is also known to be a drug target and has been identified as a potential biomarker for various neurological disorders.

The neurotransmitter glutamate is produced in the brain and is involved in the transmission of signals between neurons. It is released from the axon terminal of neurons and diffuses through the synaptic cleft to bind to receptors on the dendrites of neighboring neurons. The binding of glutamate to its receptor results in the transmission of an action potential, which is the electrical signal that carries the information from the neuron to the next.

GLUD2 is the enzyme responsible for the conversion of glutamate to gamma-aminobutyric acid (GABA), which is a neurotransmitter that has opposing effects on the activity of neurons. In low levels, GABA inhibits the activity of neurons, while in higher levels, it promotes the activity of neurons. This is important for maintaining the balance of activity in the nervous system and for proper function of the brain.

GLUD2 is a protein that is expressed in the brain and is involved in the metabolism of glutamate. It is a key enzyme in the conversion of glutamate to gamma-aminobutyric acid (GABA).

The production of glutamate from the amino acid glutamic acid is a critical step in the neurotransmission of glutamate. GLUD2 is the enzyme that converts glutamate to GABA. This conversion is critical for maintaining the proper levels of GABA in the brain and for maintaining the balance of activity in the nervous system.

In addition to its role in the metabolism of glutamate, GLUD2 has also been identified as a potential drug target. The neurotransmitter glutamate has been shown to play a crucial role in various neurological disorders, including epilepsy, schizophrenia, and Alzheimer's disease. The abnormal activity of GLUD2 has been linked to the development of these disorders, which suggests that GLUD2 may be a promising target for new therapies.

GLUD2 has also been identified as a potential biomarker for these disorders. The levels of GLUD2 have been shown to be altered in individuals with certain neurological disorders. This suggests that GLUD2 may be a useful biomarker for the diagnosis and treatment of these disorders.

In conclusion, GLUD2 is a protein that is involved in the metabolism of glutamate and has been identified as a potential drug target and biomarker for various neurological disorders. Further research is needed to fully understand the role of GLUD2 in neurotransmission and to develop new treatments based on this information.

Protein Name: Glutamate Dehydrogenase 2

Functions: Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission

The "GLUD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLUD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets